Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [843]
News [2102]
Articles [21]
Editorials [1]
Conferences [129]
elearning [2]
AlloHCT conditioning intensity in AML in complete remission with residual...
Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda...
AlloHCT conditioning intensity in AML in complete remission with residual disease ( Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda, USA )
15 Jun 2019
Inhibition of NADK strongly inhibits T-ALL cells from growing
Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK
Inhibition of NADK strongly inhibits T-ALL cells from growing ( Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK )
15 Jun 2019
Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable...
Dr Mark Roschewski - National Cancer Institute, Bethesda, USA
Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )
15 Jun 2019
Imetelstat provides durable transfusion independence in heavily transfused non...
Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France
Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) LR-MDS R/R to ESAS ( Dr Pierre Fenaux - Hôpital St Louis and Paris University, Paris, France )
14 Jun 2019
Intervention for AML patients with MRD can result in improved survival
Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart...
Intervention for AML patients with MRD can result in improved survival ( Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, USA )
14 Jun 2019
Carfilzomib and irinotecan in relapsed small cell lung cancer
Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA
Carfilzomib and irinotecan in relapsed small cell lung cancer ( Dr Susanne Arnold - UK Markey Cancer Center, Lexington, USA )
6 Jun 2019
Predictive models for treatment risk in cancer
Dr Charlotte Moser - Founder weCancerTALK
Predictive models for treatment risk in cancer ( Dr Charlotte Moser - Founder weCancerTALK )
5 Jun 2019
OpenMRS: An online medical file system to replace paper in low to middle income...
Dr Dayo Fadelu - Dana-Farber Cancer Institute, Boston, USA
OpenMRS: An online medical file system to replace paper in low to middle income countries ( Dr Dayo Fadelu - Dana-Farber Cancer Institute, Boston, USA )
5 Jun 2019
The Global Health Catalyst initiative
Wilfred Ngwa - Harvard Medical School. Boston, Massachusetts
The Global Health Catalyst initiative ( Wilfred Ngwa - Harvard Medical School. Boston, Massachusetts )
5 Jun 2019
Potential of PARP inhibitors for metastatic breast cancer
Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA
Potential of PARP inhibitors for metastatic breast cancer ( Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA )
3 Jun 2019
New agent targeting Nectin-4 produces responses in nearly half of patients with...
Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )
3 Jun 2019
No difference in survival between laparoscopic surgery and open surgery in...
Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway
No difference in survival between laparoscopic surgery and open surgery in colorectal cancer patients with liver metastases ( Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway )
3 Jun 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation